Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Formulations of chlorambucil

A technology for chlorambucil and preparations, applied in the field of compositions containing chlorambucil, can solve problems such as hindering research and development of chlorambucil

Active Publication Date: 2019-02-05
ZHUHAI BEIHAI BIOTECH CO LTD
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Lack of IV formulations has hampered development of optimal clinical dosing schedule for chlorambucil

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Formulations of chlorambucil
  • Formulations of chlorambucil
  • Formulations of chlorambucil

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0204] Example 1: Compositions containing chlorambucil and human serum albumin (HSA).

[0205] The weight ratio of the prepared chlorambucil to HSA is about 1:110.

[0206] Chlorambucil (4mg) was dissolved in methanol (0.5ml) in a vial to give a clear solution. Powdered HSA (440 mg) (natural fatty acid-free human serum albumin purchased from SeraCare Life Sciences, Cat. No. HS-455-80, which contains <0.2 mg / gm fatty acids) was dissolved In 8ml of water in a round bottom flask. At 0° C., the methanol solution of chlorambucil was slowly added dropwise to the HSA solution in the flask, and stirred. After the addition was complete, a clear solution was obtained. The resulting clear aqueous solution was lyophilized overnight to give a white solid.

[0207] A 100 mg lyophilized solid sample was reconstituted by adding 2 ml of water to give a clear aqueous solution.

Embodiment 2

[0208] Example 2: Composition comprising chlorambucil and human serum albumin (HSA).

[0209] The weight ratio of the prepared chlorambucil to HSA is about 1:80.

[0210] Chlorambucil (4mg) was dissolved in methanol (0.5ml) in a vial to give a clear solution. Powdered HSA (320 mg) (natural fatty acid-free human serum albumin purchased from SeraCare Life Sciences, Cat. No. HS-455-80, which contains <0.2 mg / gm fatty acids) was dissolved In 8ml of water in a round bottom flask. At 0° C., the methanol solution of chlorambucil was slowly added dropwise to the HSA solution in the flask, and stirred. After the addition was complete, a clear solution was obtained. The resulting clear aqueous solution was lyophilized overnight to give a white solid.

[0211] A 100 mg lyophilized solid sample was reconstituted by adding 2 ml of water to give a clear aqueous solution.

Embodiment 3

[0212]Example 3: Compositions containing chlorambucil and human serum albumin (HSA).

[0213] The weight ratio of the prepared chlorambucil to HSA is about 1:110.

[0214] Chlorambucil (4mg) was dissolved in methanol (0.5ml) in a vial to give a clear solution. HSA solution (440mg, 2.2ml) (purchased from Jeter Behring (CSL Behring) for infusion with 20% human serum albumin solution (product name: AlbuRx)) was added to 5.8ml of water in the round bottom flask, HSA solution (8ml) was obtained. At 0° C., the methanol solution of chlorambucil was slowly added dropwise to the HSA solution in the flask, and stirred. After the addition was complete, a clear solution was obtained. The resulting clear aqueous solution was lyophilized overnight to give a white solid.

[0215] A 100 mg lyophilized solid sample was reconstituted by adding 2 ml of water to give a clear aqueous solution. When visually observed after standing at room temperature for 3 hours, the clear aqueous solution r...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

This document relates to an aqueous composition comprising chlorambucil and human serum albumin, wherein the chlorambucil and the human serum albumin in the aqueous composition have a ratio by weightfrom about 1:10 to about 1:2000, wherein the aqueous composition comprises at least one water-miscible organic solvent. This document also relates to a solid composition comprising chlorambucil and human serum albumin. This document also relates to a liquid pharmaceutical composition comprising the solid composition comprising the chlorambucil and the human serum albumin, and a pharmaceutically acceptable carrier.

Description

technical field [0001] This document relates to compositions and formulations for the treatment of proliferative diseases, more particularly to compositions comprising chlorambucil. Background technique [0002] Chlorambucil is a nitrogen mustard that acts as a bifunctional alkylating agent and is used as a medicament. Chlorambucil is mainly used as an antineoplastic agent to treat cancers of the blood and lymphatic system, such as Hodgkin's and non-Hodgkin's lymphomas, chronic lymphocytic leukemia and primary (Waldenstrom ) macroglobulinemia. It is also used as a chemotherapeutic agent for Kaposi's sarcoma, as well as breast, lung, cervical, ovarian and testicular cancers. Chlorambucil is an immunosuppressant that has been used in the treatment of rheumatoid arthritis, systemic lupus erythematosus, acute and chronic glomerulonephritis, nephrotic syndrome, psoriasis, Wegener's granulomatosis, Chronic active hepatitis and cold agglutinin disease. [0003] Chlorambucil (L...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07C229/40C07K14/76A61K9/00
CPCA61K9/0019A61K9/19A61K38/385A61K45/06A61K31/196A61K9/08A61K2300/00C07C229/40A61K47/12A61K47/24
Inventor 孙群
Owner ZHUHAI BEIHAI BIOTECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com